CN102836247A - Tangerine extract composition for feminite care - Google Patents
Tangerine extract composition for feminite care Download PDFInfo
- Publication number
- CN102836247A CN102836247A CN201210337406XA CN201210337406A CN102836247A CN 102836247 A CN102836247 A CN 102836247A CN 201210337406X A CN201210337406X A CN 201210337406XA CN 201210337406 A CN201210337406 A CN 201210337406A CN 102836247 A CN102836247 A CN 102836247A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- parts
- vitamin
- feminine care
- hesperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 239000000284 extract Substances 0.000 title abstract description 8
- 241000675108 Citrus tangerina Species 0.000 title abstract 4
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 22
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 21
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 13
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 13
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 13
- 229940025878 hesperidin Drugs 0.000 claims abstract description 13
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 13
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 11
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 11
- 239000011718 vitamin C Substances 0.000 claims abstract description 11
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims abstract description 10
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims abstract description 10
- 229930019673 naringin Natural products 0.000 claims abstract description 10
- 229940052490 naringin Drugs 0.000 claims abstract description 10
- VHLJDTBGULNCGF-UHFFFAOYSA-N Limonin Natural products CC1(C)OC2CC(=O)OCC23C4CCC5(C)C(CC(=O)C6OC56C4(C)C(=O)CC13)c7cocc7 VHLJDTBGULNCGF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960001587 hesperetin Drugs 0.000 claims abstract description 9
- 235000010209 hesperetin Nutrition 0.000 claims abstract description 9
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 claims abstract description 9
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 claims abstract description 9
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 claims abstract description 9
- KBDSLGBFQAGHBE-MSGMIQHVSA-N limonin Chemical compound C=1([C@H]2[C@]3(C)CC[C@H]4[C@@]([C@@]53O[C@@H]5C(=O)O2)(C)C(=O)C[C@@H]2[C@]34COC(=O)C[C@@H]3OC2(C)C)C=COC=1 KBDSLGBFQAGHBE-MSGMIQHVSA-N 0.000 claims abstract description 9
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 claims abstract description 9
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 claims description 9
- 108010084210 citrin Proteins 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 235000020971 citrus fruits Nutrition 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000010413 mother solution Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 6
- 230000001954 sterilising effect Effects 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 4
- 210000000170 cell membrane Anatomy 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 241000233866 Fungi Species 0.000 abstract description 2
- 241000700605 Viruses Species 0.000 abstract description 2
- 244000045947 parasite Species 0.000 abstract description 2
- 230000003405 preventing effect Effects 0.000 abstract description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 abstract 2
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 abstract 2
- 229910021529 ammonia Inorganic materials 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000813 microbial effect Effects 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 239000007788 liquid Substances 0.000 description 16
- 230000000844 anti-bacterial effect Effects 0.000 description 10
- 239000007921 spray Substances 0.000 description 10
- 238000011160 research Methods 0.000 description 8
- 210000001215 vagina Anatomy 0.000 description 6
- 241000222122 Candida albicans Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- -1 flavone compound Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 241001672694 Citrus reticulata Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 4
- 229930003944 flavone Natural products 0.000 description 4
- 235000011949 flavones Nutrition 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 4
- 241000207199 Citrus Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 231100000021 irritant Toxicity 0.000 description 3
- 229940087305 limonene Drugs 0.000 description 3
- 231100000286 mucous membrane, eye irritation or corrosion testing Toxicity 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 241000305071 Enterobacterales Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010018275 Gingival atrophy Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 208000024283 Gingival haemorrhages Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000003167 anti-vitamin Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 201000005562 gingival recession Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002630 limonoids Chemical class 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012422 test repetition Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a tangerine extract composition for feminite care, which is composed of the following components in parts by weight: 0.2 to 18 parts of hesperidin, 0.04 to 1.24 parts of neohesperidin, 0.015 to 0.86 parts of naringin, 0.01 to 0.5 parts of limonin, 0.05 to 2.5 parts of vitamin P, 0.03 to 0.85 parts of hesperetin and 0.25 to 13.8 parts of vitamin C. The tangerine extract composition for feminite care provided by the invention has the following technical effects: the synergy of the components is realized, the hesperidin, the neohesperidin, the naringin, the limonin, the vitamin P, the hesperetin and the vitamin C are jointly functioned on preventing the cell plasma membranes from absorbing an ammonia acid and blocking the cell respiration, so that the effect on damaging the microbial cell membranes is achieved, and the effect on effectively killing the harmful microorganisms including bacteria, fungi, viruses and parasites and the like is realized. The tangerine extract composition is a natural physical sterilizing product in a real sense.
Description
Technical field
The present invention relates to a kind of Fructus Citri tangerinae collection compositions that is used for feminine care, belong to the medicines and health protection technical field.
Background technology
Fructus Citri tangerinae collection (being Citrus reticulata Blanco extract) has the bactericidal activity history of this existing centuries of research; Like " Pericarpium Citri Reticulatae extraction of active ingredients and bacteriostasis research such as hesperidin " (Ma Qingyi; Chen Chuntao; Jing Xiaoyan Yuan Weixia) points out hesperidin under acid condition in the research, because hesperidin is all strengthened with its ability that suppresses antibacterial and mycete of synergism of acid greatly.Hesperidin has also produced strong anti-mildew effect in the collaborative activity that suppresses antibacterial that not only strengthened down of acid." research of flavone compound and progress of application in the Citrus " (Peng Yan; Sheng Xuefei; Wu Dan Chen Jianchu) points out in the Citrus physiologically actives such as main flavone compound that exists and antioxidation thereof, anticancer disease, angiocardiopathy preventing, antiinflammatory, antiallergic, inhibition microorganism in the research.The development and use situation of Citrus flavone compounds at aspects such as food, medicine, animal feeds has been discussed simultaneously." peel of Citrus reticulata Blanco functional components present Research and development prospect " (closed Haining; Diao Xiaoqin; Zhang Runguang) from essential oil, pectin, natural pigment, dietary fiber, flavone compound and six aspects of limonoid; Summarized the present Research of functional activity composition in the peel of Citrus reticulata Blanco, and its extremely valuable development prospect has been looked forward to." the bacteriostasis property research of natural activity monoterpene-limonene " (Wang Xuemei; Chen Hui; Li Xuejiao, Sun Yonghong, high glow) work out limonene escherichia coli, bacillus subtilis, bacillus thuringiensis, beer yeast, bakery yeast and aspergillus niger are all had the better inhibited effect; Especially better to beer yeast and bakery yeast inhibition effect, have broad spectrum antibacterial; Point out also that in addition limonene as natural antiseptic agent, has good application prospects.
The Fructus Citri tangerinae collection is nontoxic organic sterilising prods.It demonstrates the inhibitory action to bacterial growth when test tube is tested, can also suppress some viral infection ability simultaneously.Therefore this extract quilt is extensively as the disinfection solvent composition, and food or cosmetics preservative are gone up as antifungal with industry, and antibacterial removes parasitic agent and anti-filterability toadstool agent use.In Italy, Fructus Citri tangerinae collection also has been one of Traditional Folk prescription since 16th century, is used to treatment and resembles calentura such as malaria and use as antibacterial.
Make a general survey of the research of above-mentioned Fructus Citri tangerinae collection (Citrus reticulata Blanco extract), all pointed out its good antibacterial that has, antioxidation, anti-corrosive fresh-keeping even other drug effect, but also do not occur the Fructus Citri tangerinae collection is carried out the product that industrialization is produced.
Summary of the invention
The objective of the invention is to overcome the weak point of prior art, a kind of Fructus Citri tangerinae collection compositions that is used for feminine care is provided.
The Fructus Citri tangerinae collection compositions that is used for feminine care of the present invention, said compositions is composed of the following components:
| Component | Component ratio |
| Hesperidin | 0.2-18 weight portion |
| Neohesperidin | 0.04-1.24 weight portion |
| Naringin | 0.015-0.86 weight portion |
| Limonin | 0.01-0.5 weight portion |
| Citrin | 0.05-2.5 weight portion |
| Hesperetin | 0.03-0.85 weight portion |
| Vitamin C | 0.25-13.8 weight portion |
Preferably,
The described Fructus Citri tangerinae collection compositions that is used for feminine care, said compositions is composed of the following components
| Component | Component ratio |
| Hesperidin | The 8-12 weight portion |
| Neohesperidin | 0.076-1.02 weight portion |
| Naringin | 0.03-0.26 weight portion |
| Limonin | 0.016-0.13 weight portion |
| Citrin | 0.08-0.15 weight portion |
| Hesperetin | 0.06-0.33 weight portion |
| Vitamin C | 5.2-8.24 weight portion |
The Fructus Citri tangerinae collection compositions that is used for feminine care of the present invention; Its preparation method is following: the citrus fruit raw material presses pulverizing broken; Add the cohobation of water post-heating, collect the effect fraction, store down in 0 ℃ to 10 ℃ after all the other residues and mother solution mix; Collect after the layering supernatant and with collect fraction before and mix adjusting PH to 3.2-5.0.
The Fructus Citri tangerinae collection compositions that is used for feminine care of the present invention,
The hesperidin proportion is the 0.2-18 weight portion, 8-12 weight portion preferably, and in this scope, hesperidin can be brought into play the antiinflammatory antiviral, strengthen the effect of vitamin C effect:
The neohesperidin proportion is the 0.04-1.24 weight portion, 0.076-1.02 weight portion preferably, and in this scope, neohesperidin assists to bring into play down capillary permeability, the anticancer effect of antibacterial kept at Citrin:
The naringin proportion is the 0.015-0.86 weight portion, 0.03-0.26 weight portion preferably, and in this scope, naringin can be brought into play the effect of antimicrobial antiphlogistic, antiviral, anti-peroxidation:
The limonin proportion is the 0.01-0.5 weight portion, 0.016-0.13 weight portion preferably, and in this scope, limonin can strengthen the naringin performance and suppress tumor, anticancer effect:
The Citrin proportion is the 0.05-2.5 weight portion, 0.08-0.15 weight portion preferably, and in this scope, Citrin can bring into play and prevent that vitamin C is oxidized, strengthen capillary permeability, prevent the effect of injury with blood-stasis:
The hesperetin proportion is the 0.03-0.85 weight portion, 0.06-0.33 weight portion preferably, and in this scope, hesperetin can be brought into play the mediation that suppresses inflammatory mediator, the effect of removing the peroxynitrite radical ion:
The vitamin C proportion is 0.25-13.8 part, 5.2-8.24 part preferably, and in this scope, vitamin C and Citrin be collaborative to strengthen the anti-vitamin C deficiency of performance, promotion collagen protein synthesis, prevent gingival atrophy and hemorrhage, antioxidative effect:
The Fructus Citri tangerinae collection compositions that is used for feminine care of the present invention has following technique effect: each composition has synergism; Hesperidin, neohesperidin, naringin, limonin, Citrin, hesperetin and vitamin C combined effect stop the cellular plasm film to absorb aminoacid; The blocking-up Cellular respiration; Thereby reaching the effect of destroy microorganisms cell membrane, play harmful microbe effects such as effective kill bacteria, fungus, virus and parasite, is pure natural physical sterilization product truly.
The specific embodiment
Embodiment 1-6 is used for the Fructus Citri tangerinae collection compositions of feminine care
The Fructus Citri tangerinae collection compositions that is used for feminine care of embodiment 1-6, composed of the following components, its component is as shown in table 1 with each component ratio:
Table 1:
Embodiment 7 is used for the spray type feminine care liquid and the effect detection thereof of the Fructus Citri tangerinae collection compositions of feminine care
The component of spray type feminine care liquid: Fructus Citri tangerinae collection compositions accounts for (0.01-0.015) % of spray type feminine care liquid weight, and surplus is a water.
Spray type feminine care liquid is carried out toxicity detect (comprising acute eye irritation test and a vaginal mucomembranous irritant test) and bactericidal effect detection.
1, acute eye irritation test
1) material and animal
With spray type feminine care liquid for being tried thing.
3 of healthy no ophthalmic NZws, regular grade, kind warren, Nanjing provides, quality certification SCXK (Soviet Union) 2007-0004 number, body weight 2.4-2.7kg, female 2, male 1.Animal feed source and card number: Jiangsu Province work in coordination with the medical bioengineering company limited, and the A that revives raises new word (2002) No. 009.
Experimental condition: regular grade laboratory animal environment, occupancy permit number: SYXK (Soviet Union) 2007-0020 number; Ambient temperature: 22 ± 2 ℃, relative humidity 40-70%; Animal is quarantined in feeding environment and adapts to 3d before the test.Key instrument: baby scale (numbering 05-713).
2) method
Test basis Ministry of Public Health (version in 2002) " disinfection technology standard " second portion 2.3.4 acute eye irritation test.
The method of inspection is following: get and tried thing 0.1ml and directly splash in the rabbit one branch hole conjunctival sac; Passive closed eyelid 4s; Use normal saline flushing behind the 30s, another eye drips with normal saline as contrast, 1h, 24h, 48h, 4d and 7d observed and recorded eye IR behind eye drip.
3) result of the test
4) conclusion
The spray type feminine care liquid of present embodiment belongs to nonirritant to the disposable eye of rabbit stimulus intensity.
2, vaginal mucomembranous irritant test
1) material and animal
With spray type feminine care liquid for being tried thing.
6 of healthy no skin disease NZws, regular grade, kind warren, Nanjing provides, quality certification SCXK (Soviet Union) 2007-0004 number, body weight 2.0-2.4kg.Animal feed source and card number: Jiangsu Province work in coordination with the medical bioengineering company limited, and the A that revives raises new word (2002) No. 009.
Experimental condition: regular grade laboratory animal environment, occupancy permit number: SYXK (Soviet Union) 2007-0020 number; Ambient temperature: 22 ± 2 ℃, relative humidity 40-70%; Animal is quarantined in feeding environment and adapts to 3d before the test.Aquesterilisa is freely drunk.Key instrument: baby scale (numbering 05-324).
2) method
Test basis Ministry of Public Health (version in 2002) " disinfection technology standard " second portion 2.3.5 vaginal mucomembranous irritant test.
The method of inspection is following: animal is divided into test group, matched group, 3 every group.Animal faces upward fixing, exposes perineum and vaginal orifice.The trumpet catheter of sterilizing is connected with the 2ml syringe, and conduit is softly inserted (4-5cm) in the animal vagina with trying thing after moistening, and slowly injects 2ml with disinfector and tried thing, extracts conduit out, accomplishes contamination.Control animals is done same the processing with normal saline.Adopt the aeroembolism method to put to death animal behind the 24h, cut open the belly and take out complete vagina, vertically cut, perusal has or not performances such as hyperemia, edema, reference when supplying pathologic sampling.Vagina is put into 10% formalin fixedly more than the 24h, choose the tissue slice at two ends with three positions of central authorities of vagina, carry out histopathological examination after the HE dyeing.
3) result of the test
Hyperemia of control animals vaginal mucosa and edema are not seen in perusal, No. 2 animal vaginas of test group Mild edema.Pathological study result sees the following form:
4) conclusion
The spray type feminine care liquid of present embodiment is 0.78 to rabbit vagina MMi index, and the vaginal mucosa stimulus intensity is a nonirritant.
3, antibacterial (Candida albicans, escherichia coli, staphylococcus aureus) effect detection
1) material and animal
With spray type feminine care liquid for being tried thing.
2) method
According to " disposable use hygienic article sanitary standard " (GB15979-2002).
Test organisms 24h slant culture is washed with PBS, and (concentration of requirement is: drip in 5mL control samples liquid with 100uL, reclaiming the bacterium number is 1*10 to process bacteria suspension
4-9*10
4Cfu/mL).
Get by each 4 pipe of test liquid (5mL) and control samples liquid (with the sample homogeneous material, equal size, but do not contain anti-biotic material, and) through sterilization treatment.
Get above-mentioned bacteria suspension, drip 100uL, uniform mixing at each in by test liquid and control samples liquid respectively; Pick up counting, effect 2,5,10,20min contain 5mL PBS in vitro with appearance liquid (0.5mL) input respectively with aseptic tweezer; Fully mixing is done suitably dilution, gets wherein 2-3 dilution factor then; Draw 0.5mL respectively, place two plates, pour into cool nutrient agar (big enterobacteria and staphylococcus aureus) or sabouraud's agar (Candida albicans) 15mL to 40-45 ℃; Rotate plate, make it full and uniform, it is dull and stereotyped that agar solidifies the back upset; Cultivate 48h (big enterobacteria and staphylococcus aureus) or 72h (Candida albicans), do the viable bacteria colony counting for 35 ℃ ± 2 ℃.
Test repetition 3 times, calculate bacteriostasis rate by following formula:
X?=?(?A-B?)?/?A?*?100?%
In the formula: X---bacteriostasis rate, %;
A---the average clump count of control sample;
B---by the average clump count of test agent.
3) result of the test such as following table
| Test item | Standard value | The result |
| Candida albicans bacteriostasis rate (%) | >=50 | 100 |
| Staphylococcus aureus bacteriostasis rate (%) | >=50 | 100 |
| Escherichia coli bacteriostasis rate (%) | >=50 | 100 |
4) conclusion: spray type feminine care liquid of the present invention is 100% to Candida albicans bacteriostasis rate, staphylococcus aureus bacteriostasis rate, escherichia coli bacteriostasis rate, and product has strong bacteriostasis.
Claims (3)
1. Fructus Citri tangerinae collection compositions that is used for feminine care is characterized in that said compositions is grouped into by following one-tenth:
。
2. the Fructus Citri tangerinae collection compositions that is used for feminine care according to claim 1 is characterized in that, is grouped into by following one-tenth:
。
3. the Fructus Citri tangerinae collection preparation of compositions method that is used for feminine care as claimed in claim 1 is characterized in that, may further comprise the steps: be raw material with the citrus fruit; The pressure pulverizing is broken; Add the cohobation of water post-heating, collect the effect fraction, store down in 0 ℃ to 10 ℃ after all the other residues and mother solution mix; Collect after the layering supernatant and with collect fraction before and mix adjusting PH to 3.2-5.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210337406.XA CN102836247B (en) | 2012-09-13 | 2012-09-13 | Tangerine extract composition for feminite care |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210337406.XA CN102836247B (en) | 2012-09-13 | 2012-09-13 | Tangerine extract composition for feminite care |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102836247A true CN102836247A (en) | 2012-12-26 |
| CN102836247B CN102836247B (en) | 2014-03-05 |
Family
ID=47364150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210337406.XA Active CN102836247B (en) | 2012-09-13 | 2012-09-13 | Tangerine extract composition for feminite care |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102836247B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511114A (en) * | 2016-11-18 | 2017-03-22 | 苏州丽舒雅生物科技有限公司 | Broad spectrum bactericidal pure natural orange extract essence and preparation method thereof |
| CN106511557A (en) * | 2016-11-18 | 2017-03-22 | 苏州丽舒雅生物科技有限公司 | Orange extract-containing natural female nursing liquid and preparation method thereof |
| CN110548078A (en) * | 2018-05-31 | 2019-12-10 | 张仁维 | Composition containing Rutaceae plant extract |
-
2012
- 2012-09-13 CN CN201210337406.XA patent/CN102836247B/en active Active
Non-Patent Citations (6)
| Title |
|---|
| 刘学仁等: "橙皮苷和橙皮素生物活性的研究进展", 《中国新药杂志》 * |
| 叶兴乾等: "柑橘属类黄酮及其生理活性 ", 《中国食品学报》 * |
| 叶兴乾等: "柑橘属类黄酮及其生理活性", 《中国食品学报》, no. 05, 30 October 2008 (2008-10-30) * |
| 张向宇等: "橘皮提取物对口腔常见致病菌的抑菌效果", 《中国消毒学杂志》 * |
| 王玉金等: "正交实验法优化枳壳提取工艺的研究", 《中国医药指南》 * |
| 罗水忠等: "柑橘类果汁中柠檬苦素的含量及其性质研究", 《食品研究与开发》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511114A (en) * | 2016-11-18 | 2017-03-22 | 苏州丽舒雅生物科技有限公司 | Broad spectrum bactericidal pure natural orange extract essence and preparation method thereof |
| CN106511557A (en) * | 2016-11-18 | 2017-03-22 | 苏州丽舒雅生物科技有限公司 | Orange extract-containing natural female nursing liquid and preparation method thereof |
| CN110548078A (en) * | 2018-05-31 | 2019-12-10 | 张仁维 | Composition containing Rutaceae plant extract |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102836247B (en) | 2014-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104274490B (en) | Bactericidal composition including source of silver ions and menthol and application thereof | |
| CN102860923B (en) | Nano-silver antibacterial liquid soap and preparation method thereof | |
| US20150264935A1 (en) | Semi-Fluidic Composition for Lubricating, Moisture Retaining, Disinfecting, Sterilizing and Method Using the Same | |
| CN104488986A (en) | Traditional Chinese medicine sterilizing liquid for clinical laboratory | |
| CN104082353A (en) | Pure traditional Chinese medicine disinfectant and preparation method thereof | |
| CN106309237A (en) | Hyaluronic acid private part care gel and preparation method thereof | |
| CN103451032B (en) | Safe and environment-friendly tea seed washing powder and preparation method thereof | |
| CN103505490B (en) | A kind of cleaning wound liquid | |
| CN102470117A (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof | |
| CN104255823A (en) | Plant bacteriostatic composition and application thereof in liquid detergent | |
| CN107737070A (en) | Sterilization, skin care hand cleaning liquid | |
| CN107836466A (en) | A kind of tea tree ethereal oil natural disinfectant agent for animals and preparation method thereof | |
| CN102836247B (en) | Tangerine extract composition for feminite care | |
| CN104127464B (en) | A kind of blumea oil eye-drops preparations and preparation method thereof | |
| CN104127779A (en) | Antibacterial and anti-inflammatory Chinese herbal medicine compound lotion and preparation method thereof | |
| CN111759885A (en) | Sophora flavescens composition, sophora flavescens gel and preparation method thereof | |
| CN111493097A (en) | Collective disinfectant for inhibiting viruses and pathogenic bacteria and preparation method thereof | |
| CN106511114A (en) | Broad spectrum bactericidal pure natural orange extract essence and preparation method thereof | |
| CN106063798A (en) | A kind of film for treating oral ulcer and preparation method thereof | |
| CN106563129B (en) | It is a kind of for wound protection composition and its formation application | |
| CN113995744A (en) | Composition and antibacterial application thereof | |
| CN102038744B (en) | High-permeability environment-friendly high-efficiency skin disinfectant and preparation method thereof | |
| CN107519248A (en) | A kind of mastadenitis of cow Chinese medicinal perfusion liquid and its preparation application method | |
| CN101804094B (en) | Medicament for killing sperms in vitro | |
| CN102166314A (en) | Oil in water type citionella oil nanoemulsion and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SUZHOU LISHUYA BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: SUZHOU YIJIE BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20141023 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20141023 Address after: Kwun Tong Road Xiangcheng Economic Development Zone, Suzhou City, Jiangsu Province, No. 1 215000 Patentee after: Suzhou Li Li Ya Biological Technology Co., Ltd. Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park 215000 Xinghu Street No. 218 BioBAY building A2 room 227 Patentee before: Suzhou Yijie Biological Technology Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Kwun Tong Road Xiangcheng Economic Development Zone, Suzhou City, Jiangsu Province, No. 1 215000 Patentee after: Dr. orange Biotechnology (Suzhou) Co., Ltd. Address before: Kwun Tong Road Xiangcheng Economic Development Zone, Suzhou City, Jiangsu Province, No. 1 215000 Patentee before: Suzhou Li Li Ya Biological Technology Co., Ltd. |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wen Zhiling Inventor before: Lou Zhiqiang |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200213 Address after: 610000 No.3, floor 19, unit 1, building 1, No.199, middle section of Tianfu Avenue, Chengdu high tech Zone, China (Sichuan) pilot Free Trade Zone, Chengdu Patentee after: Chengdu Yixiang Biotechnology Co., Ltd Address before: 215000 No. 1, Kwun Tong Road, Xiangcheng Economic Development Zone, Jiangsu, Suzhou Patentee before: Dr. orange Biotechnology (Suzhou) Co., Ltd. |